Development of vaccines to treat opioid use disorders and reduce incidence of overdose

Marco Pravetoni; Sandra D. Comer

doi:10.1016/j.neuropharm.2019.06.001

Development of vaccines to treat opioid use disorders and reduce incidence of overdose

Marco Pravetoni, Sandra D. Comer

Pharmacology

Research output: Contribution to journal › Review article › peer-review

56 Scopus citations

Abstract

Vaccines offer a promising therapeutic strategy to treat substance use disorders (SUD). Vaccines have shown extensive preclinical proof of selectivity, safety, and efficacy against opioids, nicotine, cocaine, methamphetamine, and designer drugs. Despite clinical evaluation of vaccines targeting nicotine and cocaine showing proof of concept for this approach, no vaccine for SUD has yet reached the market. This review first discusses how vaccines for treatment of opioid use disorders (OUD) and reduction of opioid-induced fatal overdoses fit within the current medication assisted treatment (MAT) portfolio, and then summarizes ongoing efforts toward translation of vaccines targeting heroin, oxycodone, fentanyl, and other opioids. This article is part of the Special Issue entitled ‘New Vistas in Opioid Pharmacology’.

Original language	English (US)
Article number	107662
Journal	Neuropharmacology
Volume	158
DOIs	https://doi.org/10.1016/j.neuropharm.2019.06.001
State	Published - Nov 1 2019

Bibliographical note

Funding Information:
Dr. Pravetoni is the inventor of “Cytokine Signaling Immunomodulators and Methods”. U.S. Provisional Patent Application No. 62/334, 167 filed on May 10, 2016. International Application No. PCT/US2017/031907 filed on May 10, 2017. In the past 36 months, Dr. Comer has served on advisory boards, received grant funding from, collaborated with, and/or consulted for: Alkermes, Braeburn, Cerecor, Charleston Labs, Clinilabs, Collegium, Corbus, Daiichi Sankyo, Depomed, Egalet, Endo, Epiodyne, Indivior, Go Medical, Inspirion Delivery Sciences, Intracellular Therapies, Janssen, KemPharm, Kures, Lyndra, Mallinckrodt, Nektar, Neurolixis, Newron, Opiant, Otsuka, Pfizer, Shin Nippon Biomedical Laboratories, and Sun Pharma. She also has received honoraria from the World Health Organization (WHO).

Funding Information:
The authors thank the National Institute of Health for support under DA038876 (Marco Pravetoni), DA041730 (Marco Pravetoni), U54DA037842 (Sandra Comer), R01DA035207 (Sandra Comer). The authors thank Dr. Carly Baehr for comments.

Publisher Copyright:
© 2019 Elsevier Ltd

Keywords

Antibody
GMP
Opioid
Opioid epidemic
Translation
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.neuropharm.2019.06.001

OpenUrl availability

Full text

Cite this

@article{26f0deb4e30b44c0abc5b2662df13597,

title = "Development of vaccines to treat opioid use disorders and reduce incidence of overdose",

abstract = "Vaccines offer a promising therapeutic strategy to treat substance use disorders (SUD). Vaccines have shown extensive preclinical proof of selectivity, safety, and efficacy against opioids, nicotine, cocaine, methamphetamine, and designer drugs. Despite clinical evaluation of vaccines targeting nicotine and cocaine showing proof of concept for this approach, no vaccine for SUD has yet reached the market. This review first discusses how vaccines for treatment of opioid use disorders (OUD) and reduction of opioid-induced fatal overdoses fit within the current medication assisted treatment (MAT) portfolio, and then summarizes ongoing efforts toward translation of vaccines targeting heroin, oxycodone, fentanyl, and other opioids. This article is part of the Special Issue entitled {\textquoteleft}New Vistas in Opioid Pharmacology{\textquoteright}.",

keywords = "Antibody, GMP, Opioid, Opioid epidemic, Translation, Vaccine",

author = "Marco Pravetoni and Comer, {Sandra D.}",

note = "Funding Information: Dr. Pravetoni is the inventor of “Cytokine Signaling Immunomodulators and Methods”. U.S. Provisional Patent Application No. 62/334, 167 filed on May 10, 2016. International Application No. PCT/US2017/031907 filed on May 10, 2017. In the past 36 months, Dr. Comer has served on advisory boards, received grant funding from, collaborated with, and/or consulted for: Alkermes, Braeburn, Cerecor, Charleston Labs, Clinilabs, Collegium, Corbus, Daiichi Sankyo, Depomed, Egalet, Endo, Epiodyne, Indivior, Go Medical, Inspirion Delivery Sciences, Intracellular Therapies, Janssen, KemPharm, Kures, Lyndra, Mallinckrodt, Nektar, Neurolixis, Newron, Opiant, Otsuka, Pfizer, Shin Nippon Biomedical Laboratories, and Sun Pharma. She also has received honoraria from the World Health Organization (WHO). Funding Information: The authors thank the National Institute of Health for support under DA038876 (Marco Pravetoni), DA041730 (Marco Pravetoni), U54DA037842 (Sandra Comer), R01DA035207 (Sandra Comer). The authors thank Dr. Carly Baehr for comments. Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = nov,

day = "1",

doi = "10.1016/j.neuropharm.2019.06.001",

language = "English (US)",

volume = "158",

journal = "Neuropharmacology",

issn = "0028-3908",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Development of vaccines to treat opioid use disorders and reduce incidence of overdose

AU - Pravetoni, Marco

AU - Comer, Sandra D.

N1 - Funding Information: Dr. Pravetoni is the inventor of “Cytokine Signaling Immunomodulators and Methods”. U.S. Provisional Patent Application No. 62/334, 167 filed on May 10, 2016. International Application No. PCT/US2017/031907 filed on May 10, 2017. In the past 36 months, Dr. Comer has served on advisory boards, received grant funding from, collaborated with, and/or consulted for: Alkermes, Braeburn, Cerecor, Charleston Labs, Clinilabs, Collegium, Corbus, Daiichi Sankyo, Depomed, Egalet, Endo, Epiodyne, Indivior, Go Medical, Inspirion Delivery Sciences, Intracellular Therapies, Janssen, KemPharm, Kures, Lyndra, Mallinckrodt, Nektar, Neurolixis, Newron, Opiant, Otsuka, Pfizer, Shin Nippon Biomedical Laboratories, and Sun Pharma. She also has received honoraria from the World Health Organization (WHO). Funding Information: The authors thank the National Institute of Health for support under DA038876 (Marco Pravetoni), DA041730 (Marco Pravetoni), U54DA037842 (Sandra Comer), R01DA035207 (Sandra Comer). The authors thank Dr. Carly Baehr for comments. Publisher Copyright: © 2019 Elsevier Ltd

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Vaccines offer a promising therapeutic strategy to treat substance use disorders (SUD). Vaccines have shown extensive preclinical proof of selectivity, safety, and efficacy against opioids, nicotine, cocaine, methamphetamine, and designer drugs. Despite clinical evaluation of vaccines targeting nicotine and cocaine showing proof of concept for this approach, no vaccine for SUD has yet reached the market. This review first discusses how vaccines for treatment of opioid use disorders (OUD) and reduction of opioid-induced fatal overdoses fit within the current medication assisted treatment (MAT) portfolio, and then summarizes ongoing efforts toward translation of vaccines targeting heroin, oxycodone, fentanyl, and other opioids. This article is part of the Special Issue entitled ‘New Vistas in Opioid Pharmacology’.

AB - Vaccines offer a promising therapeutic strategy to treat substance use disorders (SUD). Vaccines have shown extensive preclinical proof of selectivity, safety, and efficacy against opioids, nicotine, cocaine, methamphetamine, and designer drugs. Despite clinical evaluation of vaccines targeting nicotine and cocaine showing proof of concept for this approach, no vaccine for SUD has yet reached the market. This review first discusses how vaccines for treatment of opioid use disorders (OUD) and reduction of opioid-induced fatal overdoses fit within the current medication assisted treatment (MAT) portfolio, and then summarizes ongoing efforts toward translation of vaccines targeting heroin, oxycodone, fentanyl, and other opioids. This article is part of the Special Issue entitled ‘New Vistas in Opioid Pharmacology’.

KW - Antibody

KW - GMP

KW - Opioid

KW - Opioid epidemic

KW - Translation

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85071993511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071993511&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2019.06.001

DO - 10.1016/j.neuropharm.2019.06.001

M3 - Review article

C2 - 31173759

AN - SCOPUS:85071993511

SN - 0028-3908

VL - 158

JO - Neuropharmacology

JF - Neuropharmacology

M1 - 107662

ER -

Development of vaccines to treat opioid use disorders and reduce incidence of overdose

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this